Hansa Biopharma AB(GB:0RC7)
kr 44.41+4.69 (+11.81%)
GB:0RC7
Hansa Biopharma AB financials statements
kr 44.41
At close:+4.69 (+11.81%)
Hansa Biopharma AB (0RC7) Financial Statements
3 Followers
Hansa Biopharma AB Financial Overview
Hansa Biopharma AB's market cap is currently kr3.96B. The company's EPS TTM is kr-7.86; its P/E ratio is -5.69; Hansa Biopharma AB is estimated to report earnings on February 11, 2027, and the estimated EPS forecast is kr-0.87. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | kr 222.26M | kr 171.32M | kr 134.09M | kr 154.53M | kr 33.88M |
| Gross Profit | kr 138.71M | kr 87.76M | kr 70.95M | kr 116.05M | kr 18.45M |
| Operating Income | kr -520.71M | kr -637.88M | kr -788.50M | kr -576.12M | kr -539.58M |
| EBITDA | kr -483.82M | kr -642.07M | kr -705.50M | kr -554.26M | kr -538.83M |
| Net Income | kr -534.11M | kr -807.24M | kr -831.72M | kr -611.13M | kr -548.28M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | kr 701.08M | kr 405.28M | kr 732.06M | kr 1.50B | kr 888.96M |
| Total Assets | kr 1.17B | kr 800.64M | kr 1.02B | kr 1.69B | kr 1.01B |
| Total Debt | kr 933.82M | kr 1.08B | kr 866.77M | kr 791.09M | kr 35.38M |
| Net Debt | kr 232.73M | kr 673.73M | kr 134.71M | kr -705.09M | kr -615.96M |
| Total Liabilities | kr 1.25B | kr 1.39B | kr 1.19B | kr 1.08B | kr 255.24M |
| Stockholders' Equity | kr -88.99M | kr -589.83M | kr -167.88M | kr 602.91M | kr 757.57M |
| Cash Flow | |||||
| Free Cash Flow | kr -549.17M | kr -675.00M | kr -755.94M | kr -506.06M | kr -483.57M |
| Operating Cash Flow | kr -549.17M | kr -674.88M | kr -755.65M | kr -502.73M | kr -481.17M |
| Investing Cash Flow | kr 0.00 | kr -116.00K | kr -284.00K | kr 229.31M | kr -2.40M |
| Financing Cash Flow | kr 847.96M | kr 346.81M | kr -7.54M | kr 1.12B | kr -4.86M |
Currency in SEK
